{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:55:53Z","timestamp":1783612553811,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.abrep.2025.100650","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T01:47:12Z","timestamp":1765417632000},"page":"100650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Associations between substance use treatment and ketamine use: A hypothesis-generating analysis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-220X","authenticated-orcid":false,"given":"Fares","family":"Qeadan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4615-0053","authenticated-orcid":false,"given":"Shanti","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abrep.2025.100650_b0005","unstructured":"American Psychiatric Nurses Association. (2023, August). Ketamine infusion therapy: Treatment considerations [Checklist]. https:\/\/www.apna.org\/ketamine-infusion-therapy\/."},{"key":"10.1016\/j.abrep.2025.100650_b0010","doi-asserted-by":"crossref","DOI":"10.4274\/jus.galenos.2024.2024-3-13","article-title":"Ketamine-induced uropathy: The detrimental effects of chronic ketamine abuse beyond the bladder-a case report with a brief literature review","author":"Baetens","year":"2024","journal-title":"Journal of Urological Surgery"},{"issue":"4","key":"10.1016\/j.abrep.2025.100650_b0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/02791072.2015.1072653","article-title":"Long-term ketamine self-injections in major depressive disorder: Focus on tolerance in ketamine\u2019s antidepressant response and the development of ketamine addiction","volume":"47","author":"Bonnet","year":"2015","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.abrep.2025.100650_b0020","unstructured":"Centers for Disease Control and Prevention. (2024, April 25). Treatment of substance use disorders. https:\/\/www.cdc.gov\/overdose-prevention\/treatment\/index.html."},{"issue":"1","key":"10.1016\/j.abrep.2025.100650_b0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopsych.2013.08.009","article-title":"The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers","volume":"76","author":"Dakwar","year":"2014","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1016\/j.abrep.2025.100650_b0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/j.abrep.2025.100650_b0035","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jfda.2013.09.038","article-title":"Family and social aspects of substance use disorders and treatment","volume":"21","author":"Daley","year":"2013","journal-title":"Journal of Food and Drug Analysis"},{"key":"10.1016\/j.abrep.2025.100650_b0040","unstructured":"Drug Enforcement Administration. (2020, June). Ketamine [Drug fact sheet]. U.S. Department of Justice. https:\/\/www.dea.gov\/sites\/default\/files\/2020-06\/Ketamine-2020.pdf."},{"issue":"2","key":"10.1016\/j.abrep.2025.100650_b0045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5152\/alphapsychiatry.2024.241522","article-title":"Ketamine in substance use disorder treatment: A narrative review","volume":"25","author":"Famu\u0142a","year":"2024","journal-title":"Alpha Psychiatry"},{"issue":"5","key":"10.1016\/j.abrep.2025.100650_b0050","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000526079","article-title":"Substance use, substance use disorders, and co-occurring psychiatric disorders in recently incarcerated men: A comparison with the general population","volume":"28","author":"Fovet","year":"2022","journal-title":"European Addiction Research"},{"key":"10.1016\/j.abrep.2025.100650_b0055","unstructured":"Gollinge, A., & Ploussiou, H. (2025, January 21). Substance use disorders treatment options. SAMHSA Blog. https:\/\/www.samhsa.gov\/blog\/substance-use-disorders-treatment-options."},{"issue":"4","key":"10.1016\/j.abrep.2025.100650_b0060","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/bs5040477","article-title":"The key to individualized addiction treatment is comprehensive assessment and monitoring of symptoms and behavioral change","volume":"5","author":"Hilton","year":"2015","journal-title":"Behavioral Sciences"},{"key":"10.1016\/j.abrep.2025.100650_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2025.209705","article-title":"Role of ketamine in the treatment of substance use disorders: A systematic review","volume":"175","author":"Janssen-Aguilar","year":"2025","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"10.1016\/j.abrep.2025.100650_b0070","unstructured":"Janssen Pharmaceuticals, Inc. (2025, January 21). SPRAVATO\u00ae (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression [Press release]. Johnson & Johnson. https:\/\/www.jnj.com\/media-center\/press-releases\/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression."},{"issue":"4","key":"10.1016\/j.abrep.2025.100650_b0075","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/03124070802428191","article-title":"Homelessness and substance abuse: Which comes first?","volume":"61","author":"Johnson","year":"2008","journal-title":"Australian Social Work"},{"key":"10.1016\/j.abrep.2025.100650_b0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: A systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.abrep.2025.100650_b0085","series-title":"Phencyclidine toxicity","author":"Journey","year":"2023"},{"issue":"8","key":"10.1016\/j.abrep.2025.100650_b0090","first-page":"625","article-title":"Effects of ketamine on precipitated opiate withdrawal","volume":"42","author":"Jovai\u0161a","year":"2006","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.abrep.2025.100650_b0095","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212308","article-title":"Practical outpatient pharmacotherapy for alcohol use disorder","volume":"7","author":"Kim","year":"2018","journal-title":"Drugs in Context"},{"key":"10.1016\/j.abrep.2025.100650_b0100","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","article-title":"The abuse liability of ketamine: A scoping review of preclinical and clinical studies","volume":"151","author":"Le","year":"2022","journal-title":"Journal of Psychiatric Research"},{"issue":"7","key":"10.1016\/j.abrep.2025.100650_b0105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/brainsci11070856","article-title":"Therapeutic potentials of ketamine and esketamine in obsessive-compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): A review of the current literature","volume":"11","author":"Martinotti","year":"2021","journal-title":"Brain Sciences"},{"key":"10.1016\/j.abrep.2025.100650_b0110","unstructured":"National Institute on Drug Abuse. (2020, July). Addiction and health. U.S. Department of Health and Human Services, National Institutes of Health. https:\/\/nida.nih.gov\/publications\/drugs-brains-behavior-science-addiction\/addiction-health."},{"key":"10.1016\/j.abrep.2025.100650_b0115","unstructured":"National Institute on Drug Abuse. (2024, April 9). Ketamine. Research topics. National Institutes of Health. https:\/\/nida.nih.gov\/research-topics\/ketamine."},{"issue":"8","key":"10.1016\/j.abrep.2025.100650_b0120","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.ajem.2018.04.066","article-title":"Ketamine exposure demographics and outcomes over 16 years as reported to US poison centers","volume":"36","author":"Ni","year":"2018","journal-title":"The American Journal of Emergency Medicine"},{"issue":"1","key":"10.1016\/j.abrep.2025.100650_b0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jcph.1983","article-title":"Off\u2010label use of ketamine: A challenging drug treatment delivery model with an inherently unfavorable risk\u2010benefit profile","volume":"62","author":"Pai","year":"2022","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"7","key":"10.1016\/j.abrep.2025.100650_b0130","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/ajad.12803","article-title":"Trends in DMT and other tryptamine use among young adults in the United States","volume":"27","author":"Palamar","year":"2018","journal-title":"The American Journal on Addictions"},{"issue":"11","key":"10.1016\/j.abrep.2025.100650_b0135","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2105\/AJPH.2021.306486","article-title":"Trends in ketamine use, exposures, and seizures in the United States up to 2019","volume":"111","author":"Palamar","year":"2021","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.abrep.2025.100650_b0140","article-title":"Increased demand for ketamine infusions and associated complexities","volume":"295\u2013299","author":"Peskin","year":"2023","journal-title":"Journal of Pain Research"},{"key":"10.1016\/j.abrep.2025.100650_b0145","unstructured":"Rosenbaum, S. B., Gupta, V., Patel, P., & Palacios, J. L. (2025). Ketamine. In StatPearls (last updated January 30, 2024). StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470357\/."},{"issue":"3","key":"10.1016\/j.abrep.2025.100650_b0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1176\/appi.ajp.2015.15081082","article-title":"Potential risks of poorly monitored ketamine use in depression treatment","volume":"173","author":"Schak","year":"2016","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.abrep.2025.100650_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2022.795231","article-title":"Brain changes associated with long-term ketamine abuse, a systematic review","volume":"16","author":"Strous","year":"2022","journal-title":"Frontiers in Neuroanatomy"},{"key":"10.1016\/j.abrep.2025.100650_b0160","unstructured":"Substance Abuse and Mental Health Services Administration. (2023). Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/data\/report\/2022-nsduh-annual-national-report."},{"key":"10.1016\/j.abrep.2025.100650_b0165","year":"2025","journal-title":"National Survey on Drug Use and Health (NSDUH)"},{"issue":"2","key":"10.1016\/j.abrep.2025.100650_b0170","doi-asserted-by":"crossref","DOI":"10.51731\/cjht.2024.845","article-title":"Ketamine for adults with substance use disorders","volume":"4","author":"Tran","year":"2024","journal-title":"Canadian Journal of Health Technologies"},{"key":"10.1016\/j.abrep.2025.100650_b0175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jad.2024.12.108","article-title":"Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022","volume":"373","author":"Yang","year":"2025","journal-title":"Journal of Affective Disorders"},{"issue":"6","key":"10.1016\/j.abrep.2025.100650_b0180","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"American Journal of Epidemiology"},{"issue":"1","key":"10.1016\/j.abrep.2025.100650_b0185","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1192\/bjo.2021.1061","article-title":"Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review","volume":"8","author":"Walsh","year":"2022","journal-title":"BJPsych Open"},{"issue":"9","key":"10.1016\/j.abrep.2025.100650_b0190","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.2017.10697","article-title":"Considerations on the off-label use of ketamine as a treatment for mood disorders","volume":"318","author":"Wilkinson","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.abrep.2025.100650_b0195","article-title":"Global status report on alcohol and health and treatment of substance use disorders","year":"2024","journal-title":"World Health Organization"},{"issue":"1","key":"10.1016\/j.abrep.2025.100650_b0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.drugalcdep.2006.01.002","article-title":"Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths","volume":"84","author":"Wu","year":"2006","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Addictive Behaviors Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352853225000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352853225000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:12:13Z","timestamp":1783077133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352853225000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S2352853225000689"],"URL":"https:\/\/doi.org\/10.1016\/j.abrep.2025.100650","relation":{},"ISSN":["2352-8532"],"issn-type":[{"value":"2352-8532","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between substance use treatment and ketamine use: A hypothesis-generating analysis","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abrep.2025.100650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100650"}}